The Institute for Research in Biomedicine (IRB Barcelona) and oloBion have entered into a collaboration agreement to perform advanced metabolomic, proteomic and lipidomic analyses on murine and human tissue and biological fluid samples.
This partnership will enable oloBion to lend its expertise and cutting-edge mass spectrometry technology to support the Stem Cell and Cancer laboratory, led by Dr. Salvador Aznar Benitah. The goal of these studies is to deepen the understanding of metabolic alterations associated with various cancer models—including oral squamous cell carcinoma and triple-negative breast cancer—as well as in metabolically relevant tissues such as liver, muscle and adipose tissue.
oloBion brings extensive experience in metabolomics, lipidomics and proteomics, backed by state-of-the-art high-resolution mass spectrometry technology that guarantees the maximum precision in omics data. In addition, oloBion offers its proprietary software platform, oloMAP®, for the processing, integration and interpretation of collected data—optimizing analysis workflows and facilitating insights in biomedical research.
Thanks to this collaboration, IRB Barcelona will gain access to high-quality datasets that foster a deeper comprehension of the mechanisms underlying these pathologies and pave the way for novel therapeutic strategies.
This agreement reinforces both institutions’ commitment to scientific excellence and cutting-edge biomedical research, promoting a multidisciplinary approach to the study of metabolism in health and disease.
